1
项与 Anti-CLL-1 CAR-T (920th Hospital of Joint Logistics Support Force of People's Liberation Army of China) 相关的临床试验Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Myeloid Leukemia
Researchers plan to enroll a total of 100 patients with relapsed, refractory acute myeloid leukemia (AML) to receive a single dose of autologous CAR T cells.The safety of CAR T therapy was evaluated by observing adverse events after cell therapy;The efficacy of CAR-T therapy was evaluated against the outcome of patients' own past standard treatment regimens or historical data.Blood and bone marrow were collected before and 12 months after infusion to detect the number and activity of CAR T cells, and to evaluate the pharmacokinetics (PK) of CAR T cells.
100 项与 Anti-CLL-1 CAR-T (920th Hospital of Joint Logistics Support Force of People's Liberation Army of China) 相关的临床结果
100 项与 Anti-CLL-1 CAR-T (920th Hospital of Joint Logistics Support Force of People's Liberation Army of China) 相关的转化医学
100 项与 Anti-CLL-1 CAR-T (920th Hospital of Joint Logistics Support Force of People's Liberation Army of China) 相关的专利(医药)
100 项与 Anti-CLL-1 CAR-T (920th Hospital of Joint Logistics Support Force of People's Liberation Army of China) 相关的药物交易